再灌注治疗后早期纤维蛋白原耗竭与症状性颅内出血
本研究纳入1135例接受再灌注治疗的卒中患者,分析早期纤维蛋白原下降与症状性颅内出血(sICH)的关系。结果显示,仅静脉溶栓(IVT)及IVT后桥接血管内治疗(EVT)患者中,纤维蛋白原下降程度均与sICH独立相关。提示需开发更纤维蛋白特异性的溶栓药物。
要点
- 再灌注治疗后早期纤维蛋白原下降与sICH风险增加相关。
- 仅IVT患者中Δ纤维蛋白原与sICH的OR为1.929(95%CI 1.402-2.654,P<0.001)。
- IVT后EVT患者中Δ纤维蛋白原与sICH的OR为1.765(95%CI 1.135-2.743,P=0.012)。
核心结论
- 再灌注治疗(阿替普酶溶栓)后早期纤维蛋白原水平下降与症状性颅内出血相关。
研究设计与样本
- 研究纳入1135例卒中患者,均有基线和随访纤维蛋白原水平;仅IVT者在阿替普酶输注开始后2小时检测,IVT联合EVT者在EVT结束后立即检测。
主要发现
- 仅IVT患者基线纤维蛋白原为3.36±0.94 g/L,2小时后降至2.47±0.80 g/L。
- IVT后EVT患者基线纤维蛋白原为3.35±0.82 g/L,EVT结束后降至2.52±0.83 g/L。
- sICH发生率为3.9%(44例)。
- 仅IVT患者中Δ纤维蛋白原与sICH相关(OR 1.929;95%CI 1.402-2.654;P<0.001)。
- IVT后EVT患者中Δ纤维蛋白原与sICH相关(OR 1.765;95%CI 1.135-2.743;P=0.012)。
关键数值与推荐
- sICH采用ECASS II标准判定。
- Δ纤维蛋白原定义为随访纤维蛋白原减去基线纤维蛋白原。
- 阿替普酶可在发病或觉醒后9小时内基于自动化灌注成像给药。
临床怎么用
- 再灌注治疗前后监测纤维蛋白原变化可能有助于识别sICH高风险患者。
- 未来可考虑测试更纤维蛋白特异性的溶栓药物以降低出血风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- We aimed to thoroughly investigate the relationship between early fibrinogen depletion and symptomatic intracranial hemorrhage (sICH) in patients receiving reperfusion therapy including intravenous thrombolysis (IVT) with or without endovascular thrombectomy (EVT). Methods- This study included 1135 stroke patients with baseline and follow-up fibrinogen levels at 2 hours after the beginning of alteplase infusion for those with IVT only or immediately after the end of EVT for those with combined IVT and EVT. Patients received alteplase up to 9 hours after the onset or on awakening based on automated perfusion imaging. sICH was ascertained using ECASS II (The Second European-Australasian Acute Stroke Study) criteria. Δfibrinogen was calculated as follow-up fibrinogen minus baseline fibrinogen. Results- In patients with IVT only, baseline fibrinogen level was 3.36±0.94 g/L and decreased to 2.47±0.80 g/L at 2 hours after the beginning of alteplase infusion. In patients with IVT followed by EVT, baseline fibrinogen level was 3.35±0.82 g/L and decreased to 2.52±0.83 g/L immediately after the end of EVT. sICH was observed in 44 (3.9%) patients. The extent of Δfibrinogen was associated with sICH in patients with IVT only (odds ratio, 1.929; 95% CI, 1.402-2.654; P<0.001) and in those with IVT followed by EVT (odds ratio, 1.765; 95% CI, 1.135-2.743; P=0.012). Conclusions- An early decrease in fibrinogen levels was related to sICH after reperfusion therapy with alteplase. More fibrin-specific thrombolytic agents are warranted to be tested in acute ischemic stroke patients. Clinical Trial Registration- URL: https://www.clinicaltrials.gov. Unique identifier: NCT03367286.
引用
- Yan S, Zhang X, Zhang R, et al. Early Fibrinogen Depletion and Symptomatic Intracranial Hemorrhage After Reperfusion Therapy. Stroke. 2019. PMID: 31394994. doi:10.1161/STROKEAHA.119.025711
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。